000			02209nam a2200409 i 4500
001			2136422
003			StDuBDS
005			20231010110646.0
006			m|||||o||d||||||||
007			cr |||||||||||
008			210513s2021 enka fob 001|0|eng|d
020			_a9783318067996 (PDF ebook) : _cNo price
020			_z9783318067972 (pbk.) : _cNo price
020			_z9783318067996
040			_aStDuBDS _beng _cStDuBDS _erda _epn
060		4	_aWL 360
100	1		_aHughes, Stella E., _eauthor.
245	1	0	_aMultiple sclerosis. _h[e-book]
250			_aFifth edition / _bStella E. Hughes, MB, BCh, MD, FRCP, Gabrielle Macaron, MD.
264		1	_aAbingdon, Oxford : _bKarger, _c2021.
300			_a1 online resource (164 pages) : _billustrations (colour).
490	1		_aFast facts
500			_aThis edition also issued in print: 2021.
500			_aPrevious edition: published as by Mary Rensel, Orla Gray. 2016.
504			_aIncludes bibliographical references and index.
520	8		_aMultiple sclerosis (MS) is a leading cause of disability in young adults, carrying a considerable individual and societal economic burden. The development of disease-modifying therapies and updates to diagnostic criteria are leading us into a new era for MS management, both in the earliest disease phases and progressive MS. In this completely revised/fully updated edition, we present the most recent evidence on disease pathogenesis and all clinical aspects of the condition, as well as the latest on disease-modifying therapies and other potential treatments.
521			_aSpecialized.
588			_aDescription based on online resource; title from PDF title page (viewed on January 17, 2023).
650		0	_aMultiple sclerosis.
650		0	_aMultiple sclerosis _xTreatment.
650		2	_aMultiple Sclerosis.
650		2	_aMultiple Sclerosis _xtherapy.
700	1		_aMacaron, Gabrielle, _eauthor.
700	1		_aRensel, Mary. _tMultiple sclerosis. _sFourth edition.
830		0	_aFast facts.
856	4	0	_uhttps://app.kortext.com/Shibboleth.sso/Login?entityID=https://idp.eng.nhs.uk/openathens&target=https://app.kortext.com/borrow/2136422 _yEligible NHS OpenAthens account holders click here for access
999			_c96835 _d96835